Szapacs, Matt, Jian, Wenying, Spellman, Daniel, Cunliffe, Jennifer, Verburg, Elizabeth, Kaur, Surinder, Kellie, John, Li, Wenkui, Mehl, John, Qian, Mark, Qiu, Xiazi, Sirtori, Federico Riccardi, Rosenbaum, Anton I., Sikorski, Tim, Surapaneni, Sekhar, Wang, Jian, Wilson, Amanda, Zhang, Jinhui, Post, Noah, Xue, Yongjun, Goykhman, Dina, Huang, Yue, Fang, Kasie, Yuan, Long, Chen, Linzhi, Huang, Ming, Casavant, Ellen, Fu, Yunlin, Ji, Allena, Johnson, Jay, Lassman, Michael, Li, Jing, Saad, Ola, Sarvaiya, Hetal, Wang,, Yuting, Tao, Lin and Zheng, Naiyu (2023) 2022 White Paper on Recent Issues in Bioanalysis: ICH M10 BMV Guideline & Global Harmonization; Hybrid Assays; Oligonucleotides & ADC; Non-Liquid & Rare Matrices; Regulatory Inputs (Part 1A - Recommendations on Mass Spectrometry, Chromatography and Sample Preparation, Novel Technologies, Novel Modalities, and Novel Challenges, ICH M10 BMV Guideline & Global Harmonization Part 1B - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine). Bioanalysis, 15 (16). pp. 955-1016. ISSN 1757-6199

Abstract

The 16th Workshop on Recent Issues in Bioanalysis (16th WRIB) took place in Atlanta, GA, USA on September 26-30, 2022. Over 1000 professionals representing pharma/biotech companies, CROs, and multiple regulatory agencies convened to actively discuss the most current topics of interest in bioanalysis. The 16th WRIB included 3 Main Workshops and 7 Specialized Workshops that together spanned 1 week in order to allow exhaustive and thorough coverage of all major issues in bioanalysis, biomarkers, immunogenicity, gene therapy, cell therapy and vaccines. Moreover, in-depth workshops on the ICH M10 BMV final guideline (focused on this guideline training, interpretation, adoption and transition); mass spectrometry innovation (focused on novel technologies, novel modalities, and novel challenges); and flow cytometry bioanalysis (rising of the 3rd most common/important technology in bioanalytical labs) were the special features of the 16th edition. As in previous years, WRIB continued to gather a wide diversity of international, industry opinion leaders and regulatory authority experts working on both small and large molecules as well as gene, cell therapies and vaccines to facilitate sharing and discussions focused on improving quality, increasing regulatory compliance, and achieving scientific excellence on bioanalytical issues. This 2022 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2022 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 1A) covers the recommendations on Mass Spectrometry and ICH M10. Part 1B covers the Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine. Part 2 (LBA, Biomarkers/CDx and Cytometry) and Part 3 (Gene Therapy, Cell therapy, Vaccines and Biotherapeutics Immunogenicity) are published in volume 15 of Bioanalysis, issues 15 and 14 (2023), respectively.

Item Type:	Article
Keywords:	Chromatography Vaccines Biomarkers Cell- and Tissue-Based Therapy Mass Spectrometry Oligonucleotides Technology
Date Deposited:	27 Sep 2023 00:45
Last Modified:	27 Sep 2023 00:45
URI:	https://oak.novartis.com/id/eprint/51195